Developing novel, well tolerated, innovative cancer treatments

Developing novel, well tolerated, innovative cancer treatments

Cantex has obtained exclusive worldwide rights from vTv Therapeutics to develop and commercialize azeliragon, a novel antagonist of RAGE (the receptor for advanced glycation endproducts)

company featured image
  • Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well tolerated, oral cancer treatments
  • Cantex is led by Stephen Marcus, M.D., and Neil Flanzraich, seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience

 

READ MORE

pipeline featured image
  • Azeliragon targets life-threatening and disabling complications of cancer
  • Dicopp®, targets treatment refactory multiple myeloma
  • DSTAT, licensed to Chimerix, Inc. (NASDAQ: CMRX), is in Phase 3 clinical trials for acute myeloid leukemia

 

READ MORE

doctor viewing vaccine

September 14, 2021 – Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75 per share, less brokerage commissions and fees.
READ MORE

 

June 2021 – Cantex Pharmaceuticals has entered into a licensing agreement with vTv Therapeutics Inc. under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE (the receptor for advanced glycation endproducts).
READ MORE

DSTAT (formerly known as CX-01) for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML)